Research is an exciting world, and not every big trial goes the way we hope. One result that caught our attention this week deserves a few minutes of yours, because it says something about why trials like it are run at all. Then, separately, a word about a study that is open right now at our Hamilton site.
Lipoprotein(a), written Lp(a) and said out loud as “L-P-little-a”, is a particle in the blood that carries cholesterol, a cousin of the better-known LDL. Two things make it unusual. Your level is set almost entirely by your genes, so diet, exercise and statins barely move it. And roughly one person in five carries a high level, most of them without knowing, because it is not part of a routine cholesterol test.
For decades, large studies have shown that people with high Lp(a) have more heart attacks, strokes and aortic valve disease, and the genetic evidence pointed to it being a cause rather than a bystander. That made it one of the most tempting targets in cardiology. If high Lp(a) causes these events, a drug that lowers it should prevent them. Several companies set out to build that drug, and pelacarsen, developed by Ionis and Novartis, was the first to reach the finish line.
A drug can move a lab value beautifully and still not change what happens to patients.
The trial, called Lp(a)HORIZON, enrolled 8,323 people who already had cardiovascular disease and a high Lp(a) level, all of them on the usual treatments such as statins and blood pressure medicines. Participants were assigned at random to pelacarsen, an injection that tells the liver to make less of the particle, or to a placebo, and were followed for several years while the trial counted cardiovascular deaths, heart attacks, strokes and urgent procedures to reopen blocked coronary arteries. On September 4, Novartis announced the top-line result. Lp(a) came down as designed. The events it was built to prevent did not come down with it.
That gap between a lab value and a life event is the whole reason outcome trials exist. A drug can move a number beautifully and still not change what happens to people, and the only way to find out is to enrol thousands of patients, follow them for years, and count. It is slow, it is expensive, and it is the difference between a promising idea and a treatment. Novartis says the full data will be presented at a medical congress, and the details will matter: whether any group of patients did better, how far Lp(a) actually fell, and what the safety picture looked like.
Nor is the Lp(a) story finished. Other drugs that lower it by different routes, including olpasiran from Amgen and lepodisiran from Eli Lilly, are still in their own outcome trials, and until those read out no one can say whether this result is about the target or about the drug. These drugs still have promise, and it is a space worth following.
Separately: enrolling now at HMRG
We plan to share one of these most weeks: something from the wider world of research, then what is open at our site. This week it is a study for people with atrial fibrillation who cannot take a blood thinner.
Atrial fibrillation, or AFib, is an irregular heartbeat. When the heart beats unevenly, blood can slow down and pool inside it, and pooled blood can clot. A clot that travels to the brain causes a stroke, which is why AFib is treated with blood thinners. They work well, but some people cannot take them safely: patients with advanced kidney disease or on dialysis, patients who have had a serious bleed while on one, and patients who, after weighing the risks with their doctor, have chosen not to. That is the gap this study is aimed at, in a phrase we have used with local physicians: protection for patients who today go unprotected. Whether the study drugs deliver it is exactly what the trial is designed to find out.
The study is called ROXI-INCLINE, and its public listing is on ClinicalTrials.gov as NCT07430956. It is a Phase 3 trial sponsored by Regeneron, recruiting at multiple sites since April 2026, with about 2,600 participants planned. It tests two experimental antibodies, cenvacibart and amrecibart, that block a clotting protein called Factor XI. The reasoning is that Factor XI seems to matter more for the clots that cause strokes than for the everyday clotting that stops a cut from bleeding, so blocking it might prevent strokes with less bleeding than today’s blood thinners. Participants are assigned at random to one of the two antibodies or to a placebo, given by injection, and neither they nor the study team knows which. The trial counts strokes and major bleeding over up to three years, which is how it will answer both halves of the question.
In plain terms, it is looking for adults with atrial fibrillation who are at meaningful risk of stroke and who, together with their doctor, have concluded that a standard blood thinner is not a safe option. There are other criteria, and the study team walks through all of them with you before anything else happens. Taking part is voluntary, you can leave at any time, and you keep your own doctors throughout. Study medication, study visits and the monitoring that comes with them are at no cost, and participants are compensated for their time and travel.
If this sounds like you or someone you care for, call us at 289-768-9990 or send us a note and a coordinator will call you back. Please do not send health details by email. Your own doctor can also refer you, and if you have general questions about what joining a study involves, our patients page is a good place to start.